181 related articles for article (PubMed ID: 15611073)
1. Oligomers of ERBB3 have two distinct interfaces that differ in their sensitivity to disruption by heregulin.
Kani K; Warren CM; Kaddis CS; Loo JA; Landgraf R
J Biol Chem; 2005 Mar; 280(9):8238-47. PubMed ID: 15611073
[TBL] [Abstract][Full Text] [Related]
2. The extracellular domains of ErbB3 retain high ligand binding affinity at endosome pH and in the locked conformation.
Kani K; Park E; Landgraf R
Biochemistry; 2005 Dec; 44(48):15842-57. PubMed ID: 16313187
[TBL] [Abstract][Full Text] [Related]
3. Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3.
Sak MM; Szymanska M; Bertelsen V; Hasmann M; Madshus IH; Stang E
Carcinogenesis; 2013 Sep; 34(9):2031-8. PubMed ID: 23698633
[TBL] [Abstract][Full Text] [Related]
4. Simulation of homology models for the extracellular domains (ECD) of ErbB3, ErbB4 and the ErbB2-ErbB3 complex in their active conformations.
Franco-Gonzalez JF; Ramos J; Cruz VL; Martínez-Salazar J
J Mol Model; 2013 Feb; 19(2):931-41. PubMed ID: 23090500
[TBL] [Abstract][Full Text] [Related]
5. The Asn418-linked N-glycan of ErbB3 plays a crucial role in preventing spontaneous heterodimerization and tumor promotion.
Yokoe S; Takahashi M; Asahi M; Lee SH; Li W; Osumi D; Miyoshi E; Taniguchi N
Cancer Res; 2007 Mar; 67(5):1935-42. PubMed ID: 17332320
[TBL] [Abstract][Full Text] [Related]
6. Nectin-like molecule-4/cell adhesion molecule 4 inhibits the ligand-induced dimerization of ErbB3 with ErbB2.
Mizutani K; Kedashiro S; Maruoka M; Ueda Y; Takai Y
Sci Rep; 2017 Sep; 7(1):11375. PubMed ID: 28900130
[TBL] [Abstract][Full Text] [Related]
7. The N-terminal domains of neuregulin 1 confer signal attenuation.
Warren CM; Kani K; Landgraf R
J Biol Chem; 2006 Sep; 281(37):27306-16. PubMed ID: 16825199
[TBL] [Abstract][Full Text] [Related]
8. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.
Sliwkowski MX; Schaefer G; Akita RW; Lofgren JA; Fitzpatrick VD; Nuijens A; Fendly BM; Cerione RA; Vandlen RL; Carraway KL
J Biol Chem; 1994 May; 269(20):14661-5. PubMed ID: 7514177
[TBL] [Abstract][Full Text] [Related]
9. Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling.
Zhang Q; Park E; Kani K; Landgraf R
Proc Natl Acad Sci U S A; 2012 Aug; 109(33):13237-42. PubMed ID: 22733765
[TBL] [Abstract][Full Text] [Related]
10. Expression of heregulin alpha, erbB2, and erbB3 and their influences on proliferation of gastric epithelial cells.
Noguchi H; Sakamoto C; Wada K; Akamatsu T; Uchida T; Tatsuguchi A; Matsui H; Fukui H; Fujimori T; Kasuga M
Gastroenterology; 1999 Nov; 117(5):1119-27. PubMed ID: 10535875
[TBL] [Abstract][Full Text] [Related]
11. Heregulin reverses the oligomerization of HER3.
Landgraf R; Eisenberg D
Biochemistry; 2000 Jul; 39(29):8503-11. PubMed ID: 10913256
[TBL] [Abstract][Full Text] [Related]
12. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.
Feroz K; Williams E; Riese DJ
Cell Signal; 2002 Sep; 14(9):793-8. PubMed ID: 12034361
[TBL] [Abstract][Full Text] [Related]
13. Homo- and Heteroassociations Drive Activation of ErbB3.
Váradi T; Schneider M; Sevcsik E; Kiesenhofer D; Baumgart F; Batta G; Kovács T; Platzer R; Huppa JB; Szöllősi J; Schütz GJ; Brameshuber M; Nagy P
Biophys J; 2019 Nov; 117(10):1935-1947. PubMed ID: 31653451
[TBL] [Abstract][Full Text] [Related]
14. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors.
Garrett TP; McKern NM; Lou M; Elleman TC; Adams TE; Lovrecz GO; Kofler M; Jorissen RN; Nice EC; Burgess AW; Ward CW
Mol Cell; 2003 Feb; 11(2):495-505. PubMed ID: 12620236
[TBL] [Abstract][Full Text] [Related]
15. Roles of mitogen-activated protein kinase and phosphoinositide 3'-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling.
Vijapurkar U; Kim MS; Koland JG
Exp Cell Res; 2003 Apr; 284(2):291-302. PubMed ID: 12651161
[TBL] [Abstract][Full Text] [Related]
16. Suppression of heregulin β signaling by the single N-glycan deletion mutant of soluble ErbB3 protein.
Takahashi M; Hasegawa Y; Ikeda Y; Wada Y; Tajiri M; Ariki S; Takamiya R; Nishitani C; Araki M; Yamaguchi Y; Taniguchi N; Kuroki Y
J Biol Chem; 2013 Nov; 288(46):32910-21. PubMed ID: 24097984
[TBL] [Abstract][Full Text] [Related]
17. Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging.
Macdonald-Obermann JL; Adak S; Landgraf R; Piwnica-Worms D; Pike LJ
J Biol Chem; 2013 Oct; 288(42):30773-30784. PubMed ID: 24014028
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.
McDonagh CF; Huhalov A; Harms BD; Adams S; Paragas V; Oyama S; Zhang B; Luus L; Overland R; Nguyen S; Gu J; Kohli N; Wallace M; Feldhaus MJ; Kudla AJ; Schoeberl B; Nielsen UB
Mol Cancer Ther; 2012 Mar; 11(3):582-93. PubMed ID: 22248472
[TBL] [Abstract][Full Text] [Related]
19. ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface.
Berger MB; Mendrola JM; Lemmon MA
FEBS Lett; 2004 Jul; 569(1-3):332-6. PubMed ID: 15225657
[TBL] [Abstract][Full Text] [Related]
20. Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer.
Mitsui K; Yonezawa M; Tatsuguchi A; Shinji S; Gudis K; Tanaka S; Fujimori S; Sakamoto C
BMC Cancer; 2014 Nov; 14():863. PubMed ID: 25416285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]